2016 Fiscal Year Final Research Report
Development of ovarian cancer-specific gene therapy by liposome-processed oncolytic adenovirus
| Project/Area Number |
26462527
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Ehime University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 産婦人科学 |
|---|
| Outline of Final Research Achievements |
Negatively charged adenovirus was processed with positively charged liposomal DOPE/DOTAP/EPC formulated at a concentration of 8 mM at a ratio of 40%, 55%, 5% and further processed with negatively charged chondroitin sulfate having tumor specificity. Processed adenovirus showed tumor-specific anti-tumor effect even in the presence of anti-adenovirus antibody. Since weak negatively charged chondroitin sulfate was not able to sufficiently neutralize strongly positively charged liposomes, treatment with heparin having a strong negative charge shows a stronger antitumor effect even in the presence of the antibody as compared with adenovirus/liposome/chondroitin sulfate complex.
|
| Free Research Field |
外科系臨床医学・産婦人科学
|
